Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24927399 | 0.88 | KDM4E (0.32) | ALDH1A1KDM4E | |
| SCHEMBL23594364 | 0.85 | KDM4E (0.34) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL23594150 | 0.84 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL24926121 | 0.84 | KDM4E (0.33) | ALDH1A1KDM4E | |
| SCHEMBL23594107 | 0.84 | KDM4E (0.32) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL23484940 | 0.82 | L3MBTL1 (0.35) | ALDH1A1MEN1KMT2A | |
| SCHEMBL21947700 | 0.82 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL24926368 | 0.80 | HRH3 (0.40) | ALDH1A1KDM4E | |
| SCHEMBL23484936 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL23594109 | 0.79 | ALDH1A1 (0.36) | ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | ALDH1A1 4160/4885KDM4E 1022/4885MEN1 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.